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Abstract:  Anthrax  edema  toxin  (ET),  a  powerful  adenylyl  cyclase,  is  an  important 
virulence factor of Bacillus anthracis. Until recently, only a modest amount of research 
was performed to understand the role this toxin plays in the organism’s immune evasion 
strategy. A new wave of studies have begun to elucidate the effects this toxin has on a 
variety of host cells. While efforts have been made to illuminate the effect ET has on cells 
of the adaptive immune system, such as T cells, the greatest focus has been on cells of the 
innate immune system, particularly the macrophage. Here we discuss the immunoevasive 
activities that ET exerts on macrophages, as well as new research on the effects of this 
toxin on B cells.  
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1. Introduction  
Anthrax  is  an  asynchronous,  toxin-mediated  disease  caused  by  a  gram-positive  bacterium,  
Bacillus anthracis. This disease has been studied since the early nineteenth century but received much 
attention after Robert Koch formulated his famous postulates to prove that B. anthracis is the causative 
agent of anthrax. B. anthracis relies on an anti-phagocytic capsule and production of two toxins for its 
immune  evasion  abilities.  Anthrax  toxin  is  a  tripartite  A-B  type  toxin  consisting  of  the  
receptor-binding subunit, protective antigen (PA), and the catalytic subunits, lethal factor (LF) and 
edema factor (EF). PA binds two cellular receptors that are found abundantly on various host cell 
types,  capillary  morphogenesis  gene  2  (CMG2  or  ANTX2)  [1]  and  tumor  endothelial  marker  8 
(TEM8)  [2].  PA  is  undoubtedly  essential  for  virulence  of  toxigenic,  noncapsulated  strains  of 
B. anthracis, such as the attenuated Sterne strain, as PA-deficient strains were non-lethal in mice [3,4]. 
On the other hand, lethal infection with fully virulent encapsulated strains, such as Ames, was not 
dependent on the presence of PA or other toxin components [5]. Further, Ames-derived mutants that 
were non-toxigenic remained highly virulent in mice [6].  
There  are  three  vastly  different  forms  of  the  disease:  cutaneous,  gastrointestinal  (GI),  and 
inhalational. Cutaneous anthrax, with an estimated 2000 cases reported annually world-wide [7], is 
naturally acquired when spores breach the epithelial barrier through abrasions in the skin and often 
remains localized. Neutrophils have been reported to surround the necrotic, bacteria containing tissues 
[8]. GI anthrax is characterized by two forms of infection (oropharyngeal and lower GI), intestinal 
abscesses, necrosis, and hemorrhage [9]. Epithelial barrier breakdown is reported in some cases [9], 
but infections also occurred in the absence of mucosal damage [10]. Peyer’s patches in a mouse model 
of GI anthrax are the primary site of bacterial growth [10]. The early phase of inhalational anthrax 
pathogenesis is characterized by alveolar macrophages and dendritic cells (DCs) rapidly engulfing 
spores that are inhaled deeply within the lungs. While inside the host cells, spores germinate into 
replicating bacilli. Germination is an astonishingly quick event:evidence has shown that 85% of spores 
germinate  inside  murine  macrophages  within  15  minutes  [11].  Although  macrophages  were  once 
presumed to be the primary mode of transport of spores/bacilli to the mediastinal lymph nodes, a 
recent publication has provided convincing evidence that DCs are the true ―Trojan Horse‖ of the 
organism [12].  
The  second  pathogenic  phase  involves  extensive  toxin  production  by  the  replicating  vegetative 
cells. The toxins elicit major pathological consequences; because they can act both while bacilli are 
enclosed inside the host cells and after the organisms have escaped. Lethal toxin (LT; comprised of LF 
and PA) is a zinc-dependent metalloprotease that cleaves mitogen-activated protein kinase kinases 
[13]. LT is cytotoxic to endothelial cells [14], macrophages [15,16], DCs [17] and mononuclear cells 
[18].  Not  clear  is  the  exact  mechanism  with  which  the  host  cell  is  lysed  before  the  organism  is 
destroyed by the cell’s sporicidal and bactericidal mechanisms. After multiplying in the mediastinal 
lymph nodes, they disseminate into the host’s bloodstream. B. anthracis bacteremia then ensues, with 
the consequent production of large quantities of the toxins [19].  
Edema toxin (ET; consisting of EF and PA) is the other toxin produced by B. anthracis. Edema 
factor (EF) is a calcium- and calmodulin-dependent adenylyl cyclase [20] that converts ATP to cAMP 
with 1000-fold more activity than host adenylyl cyclases [21–23]. It belongs to the same class of Toxins 2010, 2  
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adenylate cyclases as Exo Y of Pseudomonas aeruginosa, adenylate cyclase of Yersinia pestis, and 
adenylyl cyclase toxin of Bordetella pertussis [24]. The intrinsic adenylyl cyclase activity of ET upsets 
the delicate physiological equilibrium inside a wide variety of host cells. For years it was speculated 
that this would lead to a suppressed immune response, but only recently has this prospect started to be 
explored [25–34]. 
During the early years of research in the field, the role of ET in the pathogenesis of anthrax was 
generally disregarded. Instead, research efforts were heavily concentrated on the enzymatic activity of 
LT. The cytotoxic nature and well-described immunosuppressive activities of LT made it the most 
attractive molecule for further studies. However, the recent culmination of studies suggests that ET 
plays more than a minor role in the disease process. The interaction of LT with an assortment of host 
cell  types  of  the  innate  and  adaptive  immune  system  has  been  thoroughly  reviewed  in  other 
publications [35,36]. Here, we review findings regarding ET interaction with a key player in the host 
innate immune defense, the macrophage. We also present new data illustrating the effects of ET on B 
cell functions that are crucial to the development of an adaptive immune response in the host.  
2. Effects of ET on Essential Macrophage Functions  
The  macrophage  is  a  critical  component  of  the  innate  immune  system.  These  cells  possess  an 
extensive arsenal of weapons designed to eliminate microbial invaders, such as efficient phagocytic 
capabilities,  chemotaxis,  activation  of  cationic  proteins  and  production  of  defensins  and  reactive 
oxygen species. In the context of anthrax infection, macrophages seem to afford protection to the host, 
as mice that have been depleted of macrophages become more susceptible to the disease [37,38]. This 
resistance to infection can be further enhanced when mice are reconstituted with macrophages before 
challenge [37,38]. Thus, it is not surprising that B. anthracis has developed methods of suppressing 
and  avoiding  certain  macrophage  functions.  It  has  been  shown  that  macrophages  are  specifically 
targeted  by  LT  and  ET,  because  toxin  receptor-negative  macrophages  were  able  to  limit  anthrax 
pathogenesis in mice infected with virulent B. anthracis Ames spores [39].  
2.1. Global Gene Changes Induced by ET  
In 2006, microarray analysis of ET-treated murine macrophages was among the first evidence of the 
powerful and wide-sweeping activity belonging to this toxin. Results showed that the expression of a 
significant number of genes responsible for key cellular functions was modulated after as little as three 
hours  of  toxin  exposure  time  [40].  This  included  genes  belonging  to  categories  such  as  immune 
response/inflammation, cell signaling, and transcription regulation. As the level of cAMP rose, so did 
the number of affected genes. After six hours, the number of altered genes in each category had at least 
doubled.  Further,  genes  involved  in  apoptosis,  adhesion,  migration,  cytoskeletal  structure  and 
metabolism were altered [40].  
ET-treatment  induced  activation  of  the  transcription  factors  AP-1  and  C/EBP-β  in  murine 
macrophages [40]. Both are major regulators of apoptosis and stress-associated immune responses, 
therefore, ET-induced activation of these components likely play major roles in affecting macrophage 
function. Additionally, anthrax toxin receptor 2 (ANTX2) was upregulated at three hours and remained 
elevated at six hours in macrophages treated with ET [40]. This may represent an evasive strategy Toxins 2010, 2  
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unique to this toxin because an increase in ANTX2 transcription may potentially cause macrophages to 
become more susceptible to binding of PA, thus facilitating entry of both anthrax toxins.  
2.2. Intracellular Signaling of ET  
The majority of early ET signaling studies involved introducing purified toxin from an extracellular 
location,  mimicking  what  likely  happens  during  later  stages  of  infection,  i.e.,  when  bacilli  are 
replicating  extracellularly  and  secreting  large  quantities  of  ET.  However,  several  studies  have 
investigated the effects of intracellular toxin production on macrophages. Banks et al. demonstrated in 
2005  that  toxins  produced  by  germinating  spores  bind  to  ANTX2  within  the  macrophage 
phagolysosome and kill them from within, but they did not delineate which of the two toxins was 
responsible for the lethality of the macrophage [41]. Kim et al. have provided recent evidence that EF 
produced from B. anthracis bacilli located within murine bone marrow-derived macrophages (BMDM) 
have the ability to modify cellular activity, such as activating protein kinase A (PKA), inducing CREB 
phosphorylation, and transcription of a downstream target gene [33]. 
Data published by Puhar et al. revealed a two-phase signaling process by ET. In Jurkat cells, the 
first  intoxication  phase  is  characterized  by  PKA-dependent  signaling,  which  results  in  CREB 
phosphorylation and gene transcription [31]. However, after a prolonged incubation, there is inhibition 
of subsequent phosphorylation of CREB by incoming stimuli. This is likely another example of the 
cell’s  negative  feedback  mechanism  to  control  the  unrestrained  synthesis  of  ET-induced  cAMP. 
Because CREB phosphorylation is a key step in T cell activation, ET intoxication may prevent an 
efficient T cell response to invading B. anthracis bacilli, thus possibly representing another strategy for 
immune evasion by the organism. ET has been shown to phosphorylate CREB in multiple other cell 
types [33,34,42], therefore, the authors proposed that it was possible that the two-phase signaling 
process described for T cells might also apply to macrophages. Further investigation is needed to 
clarify this scenario. 
In 1998, exchange protein activated by cAMP (Epac) was identified as a member of the cAMP 
signaling cascade that acts independently of PKA [43,44]. Until this point, the effects of cAMP were 
thought to be solely transduced by PKA. Epac belongs to a family of guanine exchange factors that 
directly  activate  the  small  GTPase  Rap1  and  participates  in  versatile  pathways.  In  macrophages,  
ET-generated cAMP signals through the PKA and Epac pathways in order to inhibit phagocytosis and 
actin cytoskeleton remodeling [45]. By signaling via both pathways, ET could elicit a more profound 
disruption of normal cellular signaling than if only one pathway was perturbed, and it could become 
more difficult for the host macrophage to regain control of cAMP synthesis. It appears that certain 
aspects of ET-related intracellular signaling are cell type specific. Human endothelial cells treated with 
ET underwent cytoskeletal changes and exhibited impaired chemotaxis, but these effects were due to 
activation  of  the  Epac  pathway  alone  [26].  Previous  microarray  analysis  identified  a  substantial 
downregulation  of  the  Epac-related  activator  of  Rap1,  Rap  guanine  nucleotide  exchange  factor  5 
(RapGEF5), following a six hour ET treatment of murine macrophages [40].  Toxins 2010, 2  
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2.3. ET-Induced cAMP Production and Cytotoxicity Is Cell-Dependent  
Although differing culture conditions and concentrations of EF and PA have been used in various 
studies across the literature, it appears that the intensity and duration of the cAMP response generated 
by  ET  varies  between  cell  types.  For  instance,  human  lymphocytes  are  much  more  potent  
producers of cAMP in response to ET than human neutrophils [46]. ET-treated murine macrophages  
(RAW264.7 cells) also responded with robust intracellular cAMP levels over a two hour period [46]. 
Kumar et a.l did not measure cAMP concentrations beyond two and a half hours in these experiments, 
so it is unknown if cAMP levels peaked in these cell types or continually increased over time [46]. 
We were the first to evaluate cAMP production by ET-treated human macrophages, using both 
primary  monocyte-derived  macrophages  and  a  differentiated  immortalized  cell  line  (HL-60).  ET 
significantly increased cAMP levels of both cell types by six hours post-treatment, and the effect was 
further enhanced over a 24 hour treatment period [45]. 
Another ET-induced effect that appears to be cell dependent is cytotoxicity. For instance, CHO cells 
were not killed by the toxin, while RAW 264.7 murine macrophages were susceptible to killing [47]. 
Further, cAMP levels did not correlate with cell death because some cells died in the presence of low 
cAMP concentrations, while other cell types remained viable despite high levels of cAMP production 
[47]. The dying cells did not exhibit any hallmarks of the apoptosis or oncosis pathways of cell death 
[47],  so  the  mechanism  of  the  ET-induced  cytotoxicity  remains  unknown.  Identifying  the  death 
pathway should be explored further because it could explain how ET treatment causes extensive tissue 
lesions  in  an  ET  mouse  model  [48].  The  viability  of  human  macrophages,  both  primary  and  an 
immortalized cell line, was not affected by ET exposure [45]. The effect of ET on the viability of other 
immune cells has not yet been reported in the literature.  
2.4. ET Alters the Motility and Phagocytic Activity of Macrophages  
It appears that the effect of ET on macrophage migration depends on the source of the cells. This is 
not surprising since the role of the toxins appears to differ between the murine and human models of 
disease. Kim et al. observed that ET treatment of murine BMDM’s significantly increased spontaneous 
macrophage migration [33]. This corresponded with a redistribution of actin to the cell margin and the 
formation  of  filopodia.  The  use  of  cAMP  analogs  with  specificity  to  either  the  PKA  or  EPAC 
pathways revealed that this enhanced migration was linked exclusively to PKA signaling [33].  
Alternatively, ET exposure caused reduced chemokine-directed migration of human macrophages 
[32]. This was accompanied by reduced Erk1/2 activation, suggesting that the toxin impaired immune 
cell homing by interfering with CXC and CC chemokine receptor signaling. The actin cytoskeletons of 
the immobilized macrophages were not examined in that particular study. However, Yeager et al. [45] 
used  immunofluorescence  techniques  to  visualize  and  measure  changes  in  the  cytoskeleton  of 
macrophages as a consequence of ET treatment. We showed that ET caused these cells to appear 
immobilized and remain rounded, with reduced filopodia, even in the presence of fluorescently-labeled 
phagocytic particles. We also noted reduced levels of F-actin content in ET-treated cells compared to 
that of the untreated cells [45]. Similar to Rossi Paccani et al. [32], these cells exhibited reduced 
migration towards MIP-1α (data not shown).  Toxins 2010, 2  
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We were the first to demonstrate the ability of ET to significantly decrease the phagocytic activity 
of human macrophages [45]. Primary human monocyte-derived macrophages treated with ET were not 
capable of phagocytosing virulent Ames spores to the same extent as untreated cells. We attributed this 
to the concurrent observation that the actin cytoskeleton of toxin-treated cells appeared frozen and 
unable to undergo dynamic remodeling when introduced to phagocytic particles. Actin remodeling is a 
highly dynamic process and is required in order for macrophages to carry out its normal functions. 
Thus,  the  ability  of  ET  to  paralyze  such  an  important  aspect  of  this  cell  type  is  a  dangerous 
immunoevasive mechanism held by B. anthracis. The observed defects in actin rearrangement can be 
possibly explained by the striking downregulation of multiple genes related to the cytoskeleton [40]. 
These  genes  include  and  code  for  PDZ  and  LIM  domain  protein  2  (PDLIM2),  formin-binding  
protein-1 like (FNBP1L), and switch-associated protein 70 (SWAP-70).  
The ability of ET to reduce the capacity of macrophages to phagocytose spores/bacilli is likely 
important during the later stages of infection, particularly when large amounts of ET are being secreted 
by  rapidly  multiplying  extracellular  vegetative  cells.  At  this  time,  ET-induced  suppression  of 
macrophage phagocytosis would be of tremendous advantage to the survival of the bacteria and any 
remaining viable dormant spores. ET also impairs the uptake of Sterne spores by human neutrophils 
[49]. The culmination of ET crippling two types of the host's professional phagocytes may explain how 
quickly the organism begins to multiply systemically, suddenly resulting in fulminant anthrax disease.  
2.5. Macrophage Cytokine Modulation by ET  
Very  limited  information  regarding  cytokine  production  profiles  by  macrophages  treated  with 
purified ET has been reported in the literature thus far. Shen et al. and Comer et al. showed that ET 
inhibited TNF-α production by murine BMDMs and RAW 264.7 cells, respectively, as a result of ET 
exposure, even in the presence of LPS [50,40]. ET also increased IL-6 production in BMDMs [50]. It 
is likely that this toxin is able to modulate human macrophage cytokine levels because augmented 
cAMP  levels  have  been  shown  to  influence  the  production  of  IL-1,  IL-6  and  TNF-α  in  human 
monocytes [51,52]. Further, cytokine analysis of culture supernatants and mRNA quantitation have 
shown that human monocytes respond to ET with enhanced secretion of IL-6 [53]. These cells also 
resulted in reduced production of TNF-α following dual treatments with ET and LPS [53]. Due to the 
complex interactions between these and other cytokines during infection, it is predicted that this can 
trigger serious consequences for the host response to anthrax infection. For instance, TNF-α enhances 
the  microbicidal  activity  of  macrophages  [54,55],  thus  hindering  its  production  may  allow  for 
increased survival of phagocytosed spores and/or bacilli.  
2.6. Synergistic Effects of LT and ET 
During an actual anthrax infection, it is expected that both ET and LT are secreted simultaneously. 
Although a recent publication measured the concentrations of these toxins in the blood of infected 
rabbits [19], the local concentration of LF, PA, and EF at the site of germinating and replicating 
organisms  remains  unknown.  A  vast  number  of  studies  have  examined  the  interaction  of  each 
individual anthrax toxin with diverse cell types, but a more accurate portrayal of true physiological 
consequences must include both types of toxins in the culture conditions. It is speculated that both Toxins 2010, 2  
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toxins act synergistically in vivo to disable the innate and adaptive immune responses of the host and 
the  evidence  reported  thus  far  supports  that  notion  [56].  In  vitro  studies  with  DCs  infected  with 
B. anthracis mutants expressing genes encoding LT only, ET only, or both toxins demonstrated a 
cooperative effect in suppressing cytokine production [29]. The combined mixture of both toxins also 
collectively  inhibited  T  cell  activation  [28].  However,  the  combined  effects  of  LT  and  ET  on 
macrophage functions have not been reported thus far. 
3. B Cells: An Unknown Target of ET  
A variety of B cell functions are important for the host adaptive immune  response to be fully 
effective. For instance, B cell migration is vital for B cell and T cell interactions. B cell activation is an 
important step in the adaptive immune response and a number of different cytokines and chemokines 
are  produced  by  B  cells  contributing  to  both  the  innate  and  adaptive  immune  response.  Clonal 
expansion is another B cell function vital to an effective B cell response to an antigen.  
Although still sparse in comparison to what is known about LT, the studies investigating the effects 
of ET on macrophages and other innate immune cells far surpass the published data describing the 
interaction between ET and B cells. The effects of ET have been shown to be considerable on a related 
cellular component of the adaptive immune system, T lymphocytes. For instance, although ET does 
not appear to affect T cell viability [28], it does impair its activation (inhibition of CD25 and CD69) [28], 
proliferation [28], cytokine production [27] and chemotaxis [32].  
In general, the anthrax toxins’ effects on B lymphocytes remains one of the least examined potential 
mechanisms of immune evasion that B. anthracis harbors. Fang et al. demonstrated that LT was not 
lethal for B lymphocytes but did cleave MEK-1 and 2 in PAM- and LPS-stimulated B lymphocytes [57]. 
Phosphorylation of ERK, JNK and p38 in PAM-stimulated B lymphocytes was impaired by LT [57]. 
IgM  production  and  proliferation  of  stimulated  B  lymphocytes  was  also  significantly  impaired  in  
LT-treated B lymphocytes [57]. This study demonstrated that B lymphocytes were indeed targets of 
LT, but the effects of ET on B lymphocytes were not examined. Consequently, we examined and 
showed for the first time that ET did indeed impair key B cell functions.  
3.1. B Cells Are Susceptible to ET Activity  
Because B cell viability following ET exposure has not been reported previously, this was the first 
parameter  we  examined.  It  has  previously  been  reported  that  increases  in  cAMP  induce  B  cell 
apoptosis [58], thus it was hypothesized that apoptosis would be the mechanism of toxin-mediated cell 
death. Therefore in our studies, murine B lymphocytes were treated with ET and potential cell death 
was measured by Annexin V and Propidium Iodide staining. As Figure 1 shows, there was a noticeable 
decrease in the percentage of healthy untreated control cells (50.38% AnnV
−/PI
−) in the ET group as 
early as 8 h. This correlated with an increase in the percentage of AnnV
+/PI
− cells in the ET group at 
8 h (6.23%), suggesting that some cells were undergoing early apoptosis. There was also an increase in 
the percentage of AnnV
+/PI
+ cells (42.82%) as a result of ET-treatment at this time point, which is 
indicative of late apoptosis and/or the cells that were already dead. By 24 h, the decrease in toxin-treated 
B  cell  viability  was  even  more  dramatic  (Figure  1;  only  12.28%  AnnV
−/PI
−  ET-treated  cells). 
However, only 0.73% of the ET-treated population was in the early apoptotic stage at 24 h, while the Toxins 2010, 2  
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AnnV
+/PI
+ (late apoptotic or already dead cells) population increased to 85.17%. There was also a 
small increase in the percentage of AnnV
−/PI
+ cells at 24 h (1.83%), which suggested that a small 
portion of cells were possibly undergoing necrosis. Importantly, because this staining method does not 
clearly  discriminate  between  cells  in  late  apoptosis  or  necrosis,  additional  experiments  involving 
multiple  other  time  points  are  presently  being  conducted  to  further  identify  and  characterize  the 
mechanism of ET-induced B cell death. 
Figure 1. ET effects on B lymphocyte viability. Naï ve B lymphocytes isolated from female 
BALB/c mice spleens using a Miltenyi Biotec B cell isolation kit were resuspended at  
1 ×  10
6/mL in RPMI 1640 with 10% FBS, 1 mM sodium pyruvate, 50 μM 2-ME, 100 μg/mL 
streptomycin and 100 U/mL penicillin. B cells were treated with ET (2.5 μg/mL PA and 
1.0 μg/mL EF) for 4, 8, and 24 h. Control cells were untreated. Viability was assessed by 
flow cytometry after Annexin V (eBioscience) and PI (Sigma) staining. The data are from 
one experiment and are representative of at least three independent experiments. The standard 
deviations at the 24 h time point for three individual replicates of one experiment are as 
follows: Ann
−/PI
− 47.3 ±  0.95 control and 10.83 ±  1.38 ET; Ann
+/PI
− 1.01 ±  0.4 control 
and 0.63 ±  0.1 ET; Ann
+/PI
+ 48.6 ±  0.93 control and 89.9 ±  1.32 ET; Ann
−/PI
+ 0.6 ±  0.1 control 
and 1.95 ±  0.51 ET.  
 
Fang et al. demonstrated that PA binds to B cells allowing LF to enter [57]. To determine if EF was 
able  to  bind/enter  B  lymphocytes  through  interaction  with  PA,  we  exposed  naive  murine  B 
lymphocytes to ET for 1, 4, 8, 12, and 24 h. As expected, ET treatment resulted in significant increases Toxins 2010, 2  
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in cAMP over controls at 8 h and beyond, peaking at 12 h after exposure (Figure 2), which suggested 
EF binding and possible entry of this toxin in B cells. 
Figure 2. cAMP production in ET-treated murine naï ve B lymphocytes. 5 ×  10
5 naï ve B 
lymphocytes in 200 μL were plated in each well of a 96 well tissue culture plate and 
treated with ET (2.5 μg/mL PA and 1.0 μg/mL EF) and intracellular cAMP was measured 
using a direct cAMP Enzyme Immunoassay kit according to manufacturer’s instructions 
(Assay Designs). Each bar represents the mean ±  standard error of triplicate values. The 
data are from one experiment and are representative of three independent experiments. 
Asterisks  denote  a  statistically  significant  difference  between  untreated  and  ET-treated 
cells (p < 0.05, ANOVA followed by the Student’s t-test).  
 
3.2. Anthrax ET Inhibits B Cell Migration  
Migration  of  B  lymphocytes  is  vital  for  an  effective  humoral  response  following  bacterial 
challenge.  In  the lymphoid  organs,  B  lymphocytes  localize  to  the  B  cell  follicles  due  to  CXCR5 
surface expression and local CXCL13 expression [59]. CCR7-mediated migration is required for B cell 
accumulation in the lymph nodes and migration to the B cell - T cell boundary [60,61]. Therefore, to 
determine the effects of ET on B cell migration, B lymphocytes were collected and treated with the ET 
for 4 h. ET decreased both basal migration and chemokine-directed migration (BCA-1 and MIP-3β 
chemoattractants; Figure 3). To determine whether this impaired migration was due to a change in 
chemokine receptor expression, treated cells were stained for CCR7 and CXCR5, the receptors for 
MIP-3β  and  BCA-1,  respectively.  Despite  the  ET-induced  decrease  in  migration  towards  both 
chemokines,  ET-treated  cells  had  an  increase  in  CCR7  expression  (Figure  4A)  but  no  effect  on 
CXCR5  expression  (Figure  4B).  Previous  reports  of  migration  impairment  in  the  HL-60  cell  line 
showed a decrease in F-actin content in ET-treated cells [45], and it is a possible explanation for the 
migration impairment observed here. Toxins 2010, 2  
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Figure 3. Migration of ET treated naï ve murine B lymphocytes. An aliquot (5 ×  10
5) of 
naï ve B lymphocytes were incubated with ET (2.5 μg/mL PA and 1.0 μg/mL EF) for 4 h 
and added to the upper wells of 5-µ m pore transwell migration chambers. The lower wells 
contained media alone or media with BCA-1 (1 μg/mL) and MIP-3β (1 μg/mL) (R&D 
Systems). Cells were incubated for 3 h and migrated cells were stained with Trypan Blue 
and quantitated. Values are the percent of cells added to the upper wells that migrated to 
the lower wells. The bars represent the mean ±  standard deviation of two values. The data 
are from one experiment and representative of three independent experiments. Asterisks 
denote a statistically significant difference between untreated and ET-treated cells (p < 0.05, 
ANOVA followed by the Student’s t-test).  
 
Figure 4. CCR7 and CXCR5 expression on toxin-treated naï ve B lymphocytes. 1 ×  10
6/mL 
naï ve B lymphocytes, isolated from female BALB/c mice spleens, were treated with ET 
(2.5 μg/mL PA and 1.0 μg/mL EF) and incubated for 24 h at 37 °C  and 5% CO2. Cells 
were then stained with fluorochrome labeled anti-CCR7 (eBioscience) and anti-CXCR5 
(BD  Bioscience).  CCR7  (a)  or  CXCR5  (b)  expression  was  then  measured  using  a 
FACSCanto. The numbers indicate % positive cells. The data are from one experiment and 
representative of at least three independent experiments.  
 Toxins 2010, 2  
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3.3. ET-Induced Modulation of B Cell Cytokine Production  
Antigen-stimulated B lymphocytes release the important T cell chemoattractants, MIP-1α and MIP-1β 
[62]. These chemoattractants play an important role in facilitating the B/T interactions that interrupt 
the B cell receptor-induced cell death program. Here, we showed that MIP-1α and MIP-1β production 
by stimulated B lymphocytes was impaired by ET at 48 h (Figures 5A and B). This could potentially 
impair the migration of T cells to antigen-stimulated B lymphocytes resulting in the absence of a 
CD40/CD40L cell interaction, and subsequent programmed cell death in these B lymphocytes without 
producing memory B lymphocytes and high-affinity antibodies. Alternatively, IL-6 production became 
significantly increased following ET exposure (Figure 5C). This is not surprising because cAMP has 
been shown to increase IL-6 gene expression and enhance secretion of biologically active IL-6 [63]. 
Therefore,  we  believe  that  this  increase  in  IL-6  production  is  a  direct  result  of  the  increase  in 
intracellular cAMP caused by the adenylyl cyclase activity of ET. Taken together, these data offer 
further evidence that ET upsets the development of an effective immune response, likely allowing the 
bacteria a foothold to cause serious infections.  
Figure 5. ET’s effect on cytokine and chemokine production in stimulated B lymphocytes. 
1 ×  10
6/mL naï ve B lymphocytes from Balb/c mice were treated with ET (2.5 μg/mL PA 
and 1.0 μg/mL EF) for 4 h at 37 °C  and 5% CO2. Cells were then stimulated with 5 µ g/mL 
anti-CD40 antibody, 5 ng/mL IL-4 and 5 µ g/mL anti-IgM antibody (eBioscience) for 48 h. 
After 48 h, supernatants were collected and levels of MIP-1α (a), MIP-1β (b) and IL-6 (c) 
were measured using a multi-plex cytokine array kit (Millipore). The data are expressed as 
means ±  standard deviation of triplicate values and are representative of two independent 
experiments. Asterisks denote a statistically significant difference between untreated and 
ET-treated  cells  (p  <  0.05  by  ANOVA  and  Student’s  t-test).  Unstim—unstimulated; 
Stim—stimulated B cells. 
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3.4. ET Alters B Cell Surface Marker Expression  
A number of B cell surface markers are up-regulated when B lymphocytes are activated, including 
CD86 and MHCII. The up-regulation of these markers is important for T cell/B cell interactions and 
antigen  presentation.  Here  we  show  an  increase  in  both  CD86  and  MHCII  surface  expression  in  
ET-treated naï ve B cells (Figures 6A and C). This was an unexpected observation for naï ve cells, 
however, cAMP has been shown to induce CD86 (B7-2) expression in macrophages. Further, B7 
expression was shown to be elevated in cAMP-treated B cells [64], possibly explaining these results.  
ET treatment resulted in increased CD86 expression in activated B cells (Figure 6C). This is not 
surprising because it has been demonstrated previously that cAMP analogs enhance CD40-mediated 
B cell  activation  [65].  Alternatively,  ET  exposure  slightly  impaired  MHCII  expression  when 
stimulated by anti-CD40/IL-4 (Figure 6D). This disturbance in MHCII expression could have dramatic 
effects  on  the  formation  of  T  cell-B  cell  conjugates.  This  interaction  is  needed  to  induce  the 
appropriate signals, such as cytokines and up-regulation of CD40L, from the T cell in order to achieve 
B cell proliferation and differentiation into plasma cells and memory B cells. 
Figure 6. Expression of surface markers on toxin-treated naï ve B lymphocytes. Naï ve B 
lymphocytes from Balb/c mice were exposed to ET (2.5 μg/mL PA and 1.0 μg/mL EF) for 
4 h at 37 °C  and 5% CO2. After 4 h, cells were left unstimulated (a) and (c) or stimulated 
with 5 μg/mL anti-CD40 antibody and 5 ng/mL IL-4 (b) and (d) for 24 h. Cells were then 
stained with fluorochrome labeled anti-CD86 and anti-MHCII (eBioscience). CD86 (a) and 
(b) and MHCII surface expression (c) and (d) were measured using a FACSCanto. The 
data  are  from  one  experiment  and  are  representative  of  at  least  three  independent 
experiments. In (a) and (c), the blue line represents ET treated cells and control cells are 
represented by the solid black line. In (b) and (d), unstimulated cells are the green line, ET 
treated cells are blue and control cells are the solid black line. The shaded area represents 
the isotype control.  
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4. Conclusions 
Undoubtedly, ET is a powerful weapon possessed by the biothreat agent B. anthracis. This became 
particularly evident when Firoved et al. demonstrated in vivo that ET elicited death at lower doses and 
more rapidly than LT in a mouse model [48]. Extensive tissue lesions were observed and death was 
likely due to multi-organ failure. In vitro studies with various host immune cell types performed in 
recent  years  have  contributed  to  our  overall  knowledge  of  the  immunosuppressive  and 
immunodeviation strategies of ET. Because cAMP is a second messenger molecule involved in such a 
wide variety of processes, it is no surprise that perturbation of its synthesis by ET results in a complex 
web of downstream events. For instance, immune cell migration appears to be a major target of ET 
because  it  is  common  to  multiple  cell  types  [26,32,45].  However,  gaps  still  remain  in  our 
understanding of ET activity with regard to the macrophage and B cell. Only by building a thorough 
comprehension of the interference in signaling and function that occurs within these cell types will we 
potentially discover new therapeutic strategies for the treatment of anthrax in human patients.  
Additional  research  is  needed  to  determine  the  mechanism  of  ET-mediated  B  cell  death. 
Determining whether the cytotoxic effect of ET extends to memory B cells and plasma cells is another 
important  avenue,  considering  the  rapid  waning  of  antibody  titers  in  Anthrax  Vaccine  Adsorbed 
(AVA) recipients. Previous reports indicate that ET impaired cell signaling by reducing the activation 
of ERK, MEK, and JNK in murine T cells in a cAMP dependent manner [28]. Whether ET exerts this 
same effect on B cells should be investigated. Further, does ET inhibit antibody production and class 
switching? Are these effects wide spread across all mammalian species? We are currently pursuing 
answers to these questions and others. The use of EF
− mutants in an infection model will also help 
elucidate the impact of this toxin on B cells during B. anthracis infection. 
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